22,600 Shares in Roivant Sciences Ltd. $ROIV Purchased by IFG Advisory LLC

IFG Advisory LLC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,600 shares of the company’s stock, valued at approximately $255,000.

Other large investors also recently modified their holdings of the company. Amundi boosted its holdings in Roivant Sciences by 18.1% in the first quarter. Amundi now owns 398,729 shares of the company’s stock valued at $3,991,000 after acquiring an additional 61,214 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Roivant Sciences by 16.3% during the 1st quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company’s stock valued at $40,362,000 after purchasing an additional 560,641 shares in the last quarter. Inspire Investing LLC bought a new stake in shares of Roivant Sciences during the 1st quarter valued at about $303,000. GAMMA Investing LLC boosted its stake in shares of Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock valued at $66,000 after purchasing an additional 2,945 shares in the last quarter. Finally, Peak Financial Advisors LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $472,000. 64.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Guggenheim lifted their price objective on Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. JPMorgan Chase & Co. lifted their price target on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. Leerink Partners boosted their target price on shares of Roivant Sciences from $18.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, September 18th. Finally, HC Wainwright boosted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.06.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 683,818 shares of the company’s stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $14.95, for a total value of $10,223,079.10. Following the transaction, the chief executive officer owned 1,969,767 shares in the company, valued at $29,448,016.65. The trade was a 25.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total transaction of $14,937,500.00. Following the completion of the transaction, the insider owned 36,089,108 shares in the company, valued at approximately $451,113,850. This represents a 3.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 5,228,958 shares of company stock worth $76,447,638. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Stock Down 2.0%

Shares of ROIV opened at $19.60 on Tuesday. The business’s 50 day moving average price is $15.49 and its 200-day moving average price is $12.74. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $20.08. The stock has a market cap of $13.38 billion, a P/E ratio of -28.00 and a beta of 1.23.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.